More recent 3- and 4-year Phase 3 CheckMate metastatic non-small cell lung cancer trial results were also good, if less dramatic. ESMO summary: https://dailyre

More recent 3- and 4-year Phase 3 CheckMate metastatic non-small cell lung cancer trial results were also good, if less dramatic. ESMO summary: https://dailyreporter.esmo.org/european-lung-cancer-congress-2023/elcc-2023/long-term-event-free-survival-benefits-of-neoadjuvant-nivolumab-plus-chemotherapy-for-resectable-nsclc https://dailyreporter.esmo.org/european-lung-cancer-congress... 4-year trial PR: https://news.bms.com/news/details/2023/Four-Year-Outcomes-from-Phase-3-CheckMate--9LA-Trial-Show-Durable-Long-Term-Survival-with-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-with-Two-Cycles-of-Chemotherapy-for-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer/default.aspx https://news.bms.com/news/details/2023/Four-Year-Outcomes-fr... 3-year trial abstract: https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.8521 https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.8521